Back to Search
Start Over
How Common Is Residual Inflammatory Risk?
- Source :
-
Circulation research [Circ Res] 2017 Feb 17; Vol. 120 (4), pp. 617-619. - Publication Year :
- 2017
- Subjects :
- Atherosclerosis blood
Atherosclerosis drug therapy
Atherosclerosis etiology
Atherosclerosis immunology
Biomarkers
C-Reactive Protein analysis
Cholesterol, LDL blood
Clinical Trials as Topic
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Hypercholesterolemia blood
Hypercholesterolemia complications
Hypercholesterolemia drug therapy
Hypercholesterolemia immunology
Inflammation blood
Inflammation drug therapy
Lipoproteins blood
Multicenter Studies as Topic
PCSK9 Inhibitors
Risk
Translational Research, Biomedical
Anti-Inflammatory Agents therapeutic use
Inflammation epidemiology
Subjects
Details
- Language :
- English
- ISSN :
- 1524-4571
- Volume :
- 120
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Circulation research
- Publication Type :
- Academic Journal
- Accession number :
- 28209792
- Full Text :
- https://doi.org/10.1161/CIRCRESAHA.116.310527